High Serum Carbohydrate Antigen (CA) 125 Level Is Associated With Poor Prognosis in Patients With Light-Chain Cardiac Amyloidosis

被引:3
|
作者
Li, Muzheng [1 ]
Wu, Zhijian [1 ]
Tudahun, Ilyas [1 ]
Liu, Na [1 ]
Lin, Qiuzhen [1 ]
Liu, Jiang [2 ]
Wang, Yingmin [1 ]
Chen, Mingxian [1 ]
Chen, Yaqin [1 ]
Qi, Nenghua [1 ]
Zhu, Qingyi [1 ]
Li, JunLi [3 ]
Li, Wei [4 ]
Tang, Jianjun [1 ]
Liu, Qiming [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha, Peoples R China
[3] Cent South Univ, Xiangya Hosp 2, Dept Radiol, Changsha, Peoples R China
[4] Huaihua Hosp Tradit Chinese Med, Dept Cardiol, Huaihua, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
light-chain cardiac amyloidosis; CA; 125; prognostic predictor; overall survival; biomarkers; ADVANCED HEART-FAILURE; OVARIAN-CANCER; CA-125; LEVELS; NATRIURETIC PEPTIDE; STAGING SYSTEM; TUMOR-MARKERS; CA125; ELEVATION; CYTOKINES; PERITONEAL;
D O I
10.3389/fcvm.2021.692083
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Aims: Patients with light-chain cardiac amyloidosis (AL-CA) are characterized by high levels of serum carbohydrate antigen 125 (CA 125). However, studies have not explored the correlation between CA 125 and AL-CA. The aim of this study was to explore the clinical implications of an increase in CA 125 in patients with AL-CA. Methods and Results: A total of 95 patients diagnosed with AL-CA at the Second Xiangya Hospital were enrolled in this study. Out of the 95 patients with AL-CA, 57 (60%) patients had elevated serum CA 125 levels. The mean age was 59.7 +/- 10.0 years with 44 (77.2%) men in the high serum CA 125 group, and 61.8 +/- 9.6 years with 28 (73.7%) men in the normal group. Patients with high CA 125 showed higher rates of polyserositis (79.3% vs. 60.5%, p = 0.03), higher levels of hemoglobin (117.4 +/- 21.9 g/L vs. 106.08 +/- 25.1 g/L, p = 0.03), serum potassium (4.11 +/- 0.47 mmol/L vs. 3.97 +/- 0.40 mmol/L, p = 0.049), low-density lipoprotein-cholesterol (3.0 +/- 1.6 mmol/L vs. 2.3 +/- 1.10 mmol/L, p = 0.01), and cardiac troponin T (96.0 pg/mL vs. 91.9 pg/mL, p = 0.005). The median overall survival times for patients with high or normal serum CA 125 were 5 and 25 months, respectively (p = 0.045). Multivariate Cox hazard analysis showed that treatment without chemotherapy (HR 1.694, 95% CI 1.121-2.562, p = 0.012) and CA 125 (HR 1.002, 95% CI 1.000-1.004, p = 0.020) was correlated with high all-cause mortality. The time-dependent receiver operating characteristic (t-ROC) curve showed that the prediction accuracy of CA 125 was not inferior to that of cardiac troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and lactate dehydrogenase (LDH) based on the area under the curve. Conclusions: CA 125 is a novel prognostic predictor. High serum CA 125 values are correlated with low overall survival, and the accuracy of predicting prognosis is similar to that of traditional biomarkers in AL-CA.
引用
下载
收藏
页数:11
相关论文
共 50 条
  • [31] Monitoring of Systemic Light-Chain Amyloidosis Patients Using Mass Spectrometry (MinSight) in Serum
    Mouktadi, Zarouki
    Diemont, Paul-Henri
    Di Stefano, Luciano
    Bonifay, Vincent
    Bender, Sebastien
    Pascal, Virginie
    Sirac, Christophe
    Roussel, Murielle
    Dubroc, Caroline Rouge
    Sonigo, Pierre
    BLOOD, 2023, 142
  • [32] Clinical Outcomes and Effectiveness of Heart Transplantation in Patients With Systemic Light-chain Cardiac Amyloidosis
    Jeong, Hyehyun
    Hwang, Inhwan
    Kim, Jwa Hoon
    Cho, Hyungwoo
    Kim, Min-Seok
    Lee, Sang Eun
    Choi, Hyo-In
    Jung, Sung-Ho
    Lee, Jae Won
    Yun, Tae-Jin
    Park, Jeong-Jun
    Kim, Miyoung
    Go, Heounjeong
    Park, Chan Sik
    Yoon, Dok Hyun
    Kim, Jae-Joong
    TRANSPLANTATION, 2022, 106 (11) : 2256 - 2262
  • [33] Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis
    Papathanasiou, Maria
    Jakstaite, Aiste-Monika
    Oubari, Sara
    Siebermair, Johannes
    Wakili, Reza
    Hoffmann, Julia
    Carpinteiro, Alexander
    Hagenacker, Tim
    Thimm, Andreas
    Rischpler, Christoph
    Kessler, Lukas
    Rassaf, Tienush
    Luedike, Peter
    ESC HEART FAILURE, 2022, 9 (03): : 1740 - 1748
  • [34] Effects of treatment response on echocardiographic features among patients with light-chain cardiac amyloidosis
    Briasoulis, A.
    Rempakos, A.
    Petropoulos, I.
    Bampatsias, D.
    Theodorakakou, F.
    Dimopoulos, M. A.
    Stamatelopoulos, K.
    Kastritis, E.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [35] Clinical outcomes and effectiveness of heart transplantation in patients with systemic light-chain cardiac amyloidosis
    Jeong, Hyehyun
    Hwang, Inhwan
    Kim, Jwa Hoon
    Cho, Hyungwoo
    Kim, Min-Seok
    Lee, Sang Eun
    Choi, Hyo-In
    Jung, Sung-Ho
    Lee, Jae Won
    Yun, Tae-Jin
    Park, Jeong-Jun
    Kim, Miyoung
    Go, Heounjeong
    Park, Chan Sik
    Yoon, Dok Hyun
    Kim, Jae-Joong
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S37 - S37
  • [36] Should We Amplify Cardiac Response Criteria in Patients with Cardiac Light-Chain Amyloidosis Treated with Bortezomib?
    Vazquez, J.
    Durante, A.
    Hernandez, E.
    Monivas Palomero, V.
    Mingo, S.
    Sayago, I.
    Garcia Pavia, P.
    Alonso-Pulpon, L.
    Segovia Cubero, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S169 - S169
  • [37] Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis
    Fourat Ridouani
    Thibaud Damy
    Vania Tacher
    Haytham Derbel
    François Legou
    Islem Sifaoui
    Etienne Audureau
    Diane Bodez
    Alain Rahmouni
    Jean-François Deux
    Journal of Cardiovascular Magnetic Resonance, 20
  • [38] Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis
    Ridouani, Fourat
    Damy, Thibaud
    Tacher, Vania
    Derbel, Haytham
    Legou, Francois
    Sifaoui, Islem
    Audureau, Etienne
    Bodez, Diane
    Rahmouni, Alain
    Deux, Jean-Francois
    JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE, 2018, 20
  • [39] Risk Factors and Prognostic Role of Left Atrial Enlargement in Patients With Light-chain Cardiac Amyloidosis
    Zhao, Lei
    Tian, Zhuang
    Fang, Quan
    CIRCULATION, 2015, 132
  • [40] Investigation of left ventricular function and biomarkers following treatment in patients with light-chain cardiac amyloidosis
    Wang, J.
    Yang, F.
    Zuo, L.
    Lei, C.
    Sheng, J.
    Sun, C.
    Liu, L.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1237 - 1237